🇺🇸 FDA
Patent

US 9388408

Oligonucleotide-based inhibitors comprising locked nucleic acid motif

granted A61PA61P9/00A61P9/04

Quick answer

US patent 9388408 (Oligonucleotide-based inhibitors comprising locked nucleic acid motif) held by MIRAGEN THERAPEUTICS, INC. expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
MIRAGEN THERAPEUTICS, INC.
Grant date
Tue Jul 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61P, A61P9/00, A61P9/04, A61P9/10